Whether a man is initially diagnosed with metastatic prostate cancer or progresses to have metastatic disease over time (after failure of standard first-line therapies), sooner or later they are all going to need — in consultation with their doctors — to decide on “the best” way to manage their progressive disease through sequential or concurrent use of a number of recently approved agents (always assuming that cost and access are not determining factors). … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, advanced, cabazitaxel, docetaxel, enzalutamide, metastatic, outcome, sequence, sipuleucel-T | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
